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KAJIAN  KERENTANAN  DAN  PENGHASILAN  SITOKIN  DALAM VIRUS  
DENGGI  JENIS 2 (DENV2) – MONOSIT  TERKESAN  DARIPADA  INDIVIDU  
YANG  KEKURANGAN GLUKOSA-6-FOSFAT  DEHIDROGENASE (G6PD). 
 
 
ABSTRAK 
 
 
Virus denggi adalah endemik di Semenanjung Malaysia. Manifestasi klinikal berubah-
ubah bergantung ke tempoh inkubasi virus serta tahap keimunan pesakit. Kekurangan 
Glukosa-6-fosfat dehidrogenase (G6PD) adalah prevalen di Malaysia, yang 
keberlakuannya adalah 5.2%. Dicatatkan bahawa individu kekurangan G6PD menderita 
lebih teruk jika dijangkiti infeksi denggi. Kajian ini bertujuan mengkaji kerentanan / 
suseptibiliti monosit terhadap infeksi DENV2, respons oksidatif, dan penghasilan 
sitokin dalam monosit individu yang mengalami kekurangan G6PD. Sampel darah 
dikumpulkan daripada penderma setelah mendapat kelulusan daripada Jawatankuasa 
Etika Penyelidikan USM dan Kementerian Kesihatan. Ujian G6PD dijalankan dengan 
keadah titik pendarflour (florescent spot method) diikuti dengan asai kuantitatif. 
Monosit daripada individu kekurangan G6PD dan individu yang sihat (G6PD normal) 
diasingkan dan diberikan DENV2. Kepelbagaian infeksi (multiplicity of infection, 
MOI) 0.1 dan kadar infeksi intrasel diukuir dengan sitometri aliran dan ekstrasel 
menggunakan asai plak. Tahap spesies oksidatif, anion superoksida (O2•-), nitrik oksida 
(NO), stres oksidatif dan sitokin ditentukan dan dibandingkan dengan kawalan. 
Keputusan menunjukkan bahawa kerentanan yang tinggi daripada monosit kekurangan 
G6PD terhadap DENV2 dan tahap NO dan O2•-,   secara signifikannya rendah dalam 
monosit kekurangan G6PD dibandingkan dengan kawalan-sihat.  Pada keseluruhan, 
stres oksidatif pada individu kekurangan G6PD secara signifikannya amat tinggi 
dibandingkan dengan kawalan-sihat. Kajian korelasi di antara replikasi viral dan 
xxiv 
 
keadaan oksidatif monosit mengesahkan dapatan  ini. Di samping itu, pro-inflamatori 
sitokin IL-6, IL-8, IL-12, TNF-α dan MCP-1 secara signifikannya meningkat  (P<0.05) 
dan mencapai puncak pada 48 jam dalam monosit kekurangan G6PD dibandingkan 
dengan individu sihat. Secara kontras, anti-inflamatori sitokin IL-10 secara signifikan 
lebih tinggi (P<0.05) dengan puncak maksimum pada 48 jam dan seterusnya menjadi 
semakin berkurangan. IFN-α secara signifikan berkurangan dalam monosit kekurangan 
G6PD dibandingkan dengan G6PD-normal (p<0.05). Sebagai tambahan, kajian korelasi 
di antara replikasi viral dan penghasilan sitokin menyokong hipotesis bahawa 
kekurangan G6PD, beban DENV2 yang lebih tinggi, dan stres oksidatif dalam sel boleh 
menyumbang terhadap peningkatan penghasilan sitokin inflamatori. Keputusan kajian 
menunjukkan bahawa individu yang kekurangan G6PD didapati lebih rentan terhadap 
infeksi DENV2 dibandingkan dengan individu sihat. Dengan kata lain, penghasilan 
spesies oksigen reaktif (reactive oxygen species, ROS) berkurangan dalam individu 
kekurangan G6PD. Ini menjelaskan bahawa infeksi denggi  tinggi di kawasan yang 
mana kekurangan G6PD adalah prevalen. Beban viral yang tinggi, stres oksidatif yang 
semakin meningkat, dan penghasilan sitokin yang diaruh adalah patogenesis DHF yang 
amat pemting. 
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THE STUDY OF SUSCEPTIBILITY AND CYTOKINE PRODUCTION IN 
DENGUE VIRUS TYPE 2 (DENV2)-INFECTED MONOCYTES OF 
INDIVIDUALS WITH GLUCOSE-6-PHOSPHATE DEHYDROGENASE (G6PD) 
DEFICIENCY 
 
 
 
 
ABSTRACT 
 
 
Dengue virus is endemic in peninsular Malaysia. The clinical manifestations 
vary depending on the incubation period of the virus as well as the immunity of the 
patients. Glucose-6-phosphate dehydrogenase (G6PD) deficiency is prevalent in 
Malaysia, where the incidence is 5.2%. It has been noted that G6PD-deficient 
individuals suffer from more severe clinical presentation of dengue infection. The aim 
of this study is to investigate the susceptibility of monocytes to DENV2 infection, the 
oxidative responses, and cytokine production in monocytes from G6PD-deficient 
individuals. Blood samples were collected from donors after being approved by the 
Research Ethical Committees of USM and Ministry of Health. Screening for G6PD was 
performed using the florescent spot method followed by the quantitative assay. 
Monocytes from G6PD-deficient and healthy individuals (G6PD-normal) were isolated 
and infected with DENV2, whereby multiplicity of infection (MOI) 0.1 and intracellular 
infection rate were measured by flow cytometry and extracellular by plaque assay. 
Levels of oxidative species, superoxide anions (O2•-), nitric oxide (NO), oxidative stress 
and cytokines were determined and compared with normal controls. The findings 
indicate that early and high susceptibility of monocytes with G6PD-deficiency to 
DENV2 and levels of NO and O2•-,  were significantly lower in the monocytes of 
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individuals with G6PD-deficiency compared to the healthy controls. Furthermore, the 
overall oxidative stress in individuals with G6PD-deficiency was significantly higher 
when compared to the healthy controls. Correlation studies between viral replication 
and monocyte oxidative state further confirmed these findings. Moreover, pro-
inflammatory cytokines IL-6, IL-8, IL-12, TNF-α and MCP-1 were significantly 
increased (P<0.05) and peaked on 48 hours in infected G6PD-deficient monocytes 
compared to those obtained from healthy individuals. Anti-inflammatory cytokine IL-10 
was significantly higher (P<0.05) with maximum peak at 48 hours and decreased 
thereafter. IFN-α were significantly reduced in infected monocytes with G6PD-
deficiency compared to G6PD-normal (p<0.05). In addition, correlation studies between 
viral replication and cytokine production confirmed and thus supported the hypothesis 
that in G6PD-deficiency, the higher DENV2 load, and oxidative stress in the cell may 
contribute to enhance production of inflammatory cytokines. The results of the study 
demonstrated that individuals with G6PD-deficiency are more susceptible to DENV2 
infection compared to healthy individuals. The likely explanation for this is reduced 
production of reactive oxygen species (ROS) in individuals with G6PD deficiency. This 
may explain the reason for high prevalence of dengue infection in areas where G6PD 
deficiency is prevalent. High viral load, elevated oxidative stress and induce cytokines 
production are the most important of pathogenesis of DHF.  
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CHAPTER ONE 
 
1.0   Introduction 
Dengue infection disease is a leading cause of morbidity and mortality in the 
tropics and subtropics, and can lead to extensive outbreaks in urban areas (Dammert et 
al., 2009). The disease is a global problem, given that as many as 100 million people are 
infected, of whom 25,000 die annually (Gubler & Meltzer, 1999). Dengue virus (DENV) 
is primarily transmitted to humans through the bite of infected Aedes mosquitoes, 
particularly Aedes aegypti (Green & Rothman, 2006). Dengue infection is caused by 
DENV, a positive-strand RNA virus of the family Flaviviridae. Distinct variations or 
serotypes of the virus include DENV1, DENV2, DENV3, and DENV4. All four 
serotypes are capable of causing a full spectrum of the disease symptoms, with several 
degrees of severity (McBride & Bielefeldt-Ohmann, 2000).  
A significant percentage (~80%) of individuals infected with DENV show only 
mild symptoms, such as dengue fever (DF), whilst some develop a more severe dengue 
illness called dengue haemorrhage fever (DHF)/dengue shock syndrome (DSS) 
(Whitehorn & Farrar, 2010). DF is a self-limiting illness characterized by fever, 
headache, myalgia, arthralgia, nausea, and fatigue (Whitehorn & Farrar, 2010). The high 
viral load in DHF/DSS patients can be a life-threatening form of dengue infection 
characterized by a high fever, haemorrhage, vascular permeability, thrombocytopenia 
and shock (Rigau-Pérez et al., 1998). DHF/DSS is one of the leading causes of 
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paediatric hospitalization in Southeast Asia and has become endemic in all Pacific 
Countries. 
DENV2 has been involved in most Dengue outbreaks in the last 20 years and is 
associated with the severity of the disease‘s outcome (Méndez et al., 2012). Moreover, 
several epidemic reports from different studies indicated that a severity of dengue 
infection was associated with a higher titer DENV2 viremia than the other DENV 
serotypes (Balmaseda et al., 2006; Clyde et al., 2006). In addition, DENV2 has been 
identified as a cause of DHF/DSS, rather than other serotypes of DENVs (Hesse, 2007). 
In Malaysia, DENV2 emerged as the major serotype responsible for recent outbreaks of 
dengue infection (Chee & AbuBakar, 2003).  
Monocytes have been considered the major target cells of DENV replication by a 
number of authors (O'Sullivan & Killen, 1994; Chao et al., 2008). They act with the aim 
to regulate the mechanism of the immune system during infection, resulting in 
production of several cytokines/chemokines and chemical mediators. These cytokines 
include tumour necrosis factor alpha (TNF-α) (Hober et al., 1996), interferon alpha 
(IFN-α) (Kurane & Ennis, 1988), interleukin-6 (IL-6) (Chaturvedi et al., 1999), 
interleukin-8 (IL-8) (Chaturvedi et al., 2000; Bosch et al., 2002), interleukin-10 (IL-10), 
interleukin-12 (IL-12) (Green et al., 1999b), and monocyte chamoattarctic protein-1 
(MCP-1) (Yang et al., 1995), which play a key role in both innate and adaptive immune 
responses. Therefore, these cytokines play an important role in enhanced activation of 
other immune cells that may contribute to the DHF pathogenesis, and they have been 
implicated widely in conditions associated with vascular leakage, as well as hemorrhagic 
disorders in DHF/DSS patients (Martina et al., 2009). Therefore, inflammatory and anti-
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inflammatory cytokines play an important role in the pathogenesis of dengue virus 
infection and serum levels of certain cytokines are elevated during dengue infection 
(Martina et al., 2009). 
Dengue haemorrhagic fever is one of the serious causes of morbidity and 
mortality in children, in contrast to other infections in Southeast Asian countries 
(Dejnirattisai, 2004). DHF is now a leading cause of hospitalization and death among 
children (Dejnirattisai, 2004). However, it is not entirely clear why some individuals are 
more at risk of severe forms DHF/DSS of dengue infection while others are not. 
The pathogenesis of DENV remains unclear, due to the complex interplay of 
viral and host factors. Several conducted studies identified the risk factors associated 
with the severity of disease, including the specific serotype of DENV, the host immune 
status, age, and the genetic background of the patients (Clyde et al., 2006; Noisakran & 
Perng, 2008). The data from genetic epidemiology studies has demonstrated that a 
certain host susceptible genes promote the development of severe DENV infection 
(Chaturvedi et al., 2006), particularly alleles of human leukocyte antigen (HLA) class I 
and II (Lan et al., 2008). Additionally, polymorphism in gene‘s coding for TNF-α 
(Fernández‐Mestre et al., 2004), transforming growth factor β (TGFβ) (Chen et al., 
2009), and Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-
integrin (DC-SIGN) (Sakuntabhai et al., 2005) have been linked with an increased risk 
of severe dengue complications. Moreover, another genetic abnormality that is reported 
to have a link with DHF/DSS is the deficiency of glucose-6-phosphate dehydrogenase 
(G6PD)—an ubiquitous X-linked enzyme.  
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G6PD deficiency is primarily found in populations originating from tropical and 
subtropical areas of the world, and its geographic distribution is similar to that of 
malaria. G6PD deficiency, a common enzymopathy in human cells, enhances the viral 
replication (Ho et al., 2008; Wu et al., 2008) and cytokine production (Wilmanski et al., 
2007). Although the relationship between G6PD deficiency and cytokine modulation is 
very important, it has not been investigated thus far. Intracellular redox status changes in 
G6PD-deficient cells may have an impact on a modulator of cytokine production, 
thereby potentially increasing the severity of microbial infection complications 
(Wilmanski et al., 2007). Moreover, modulator of cytokine production was found to 
influence the antiviral mechanism of G6PD-deficient cells (Wu et al., 2008). 
1.1 Rationale of the Study 
Globally, dengue infection continues to affect more than 2.5 billion people living 
in 120 countries in endemic areas at risk of dengue infection (Chaturvedi et al., 2006; 
Chaturvedi & Nagar, 2008). Approximately 40% of the world‘s population live in areas 
where the disease can be acquired from mosquitoes (Morens & Fauci, 2008). Recent 
epidemic reports from Western Pacific, Southeast Asia, Eastern Mediterranean, Africa 
and some parts of South America have demonstrated that DENV infection is a serious 
cause of morbidity and mortality, with much higher prevalence compared to other 
infections (Halstead, 2007). The number of DF cases has increased 30-fold in the last 50 
years, and the associated complications cause an estimated 100 million infections, 
500,000 hospitalizations by DHF, and 25,000 deaths annually (Phillips, 2008). 
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In Malaysia, the first case of DF was reported in 1902 (Skae, 1902). Penang was 
the first to be affected with DF (Rudnick et al., 1965). The primary DHF outbreak was 
also recorded in Penang in 1962 (Rudnick et al., 1965; George, 1992). Currently, DF 
and DHF have become the major public health problems in Malaysian Peninsula 
(Wallace et al., 1980; George, 1992), all states, including East Malaysia, similarly 
affected. More recently, a large outbreak of DENV infection occurred in 2008, with the 
total of 49355 cases and 122 deaths, according to the Ministry of Health reports. 
Annually, epidemiology of the disease and the number of cases increased in all 
Malaysian states. Clearly, there is an urgent need to determine whether genetic factors, 
rather than environmental factors, are associated with increased prevalence of dengue 
fever.  
G6PD deficiency and dengue infection are still major health problems in 
countries where these diseases are common, such as Malaysia. At present, our 
understanding of the pathogenesis of dengue virus is incomplete, especially in affected 
individuals who suffer from genetic diseases such as G6PD-deficiency, thalassemia, and 
sickle cell anaemia. G6PD deficiency is the most common enzymopathy in human cells, 
which affects approximately more than 500 million individuals throughout the world 
(Sirdah et al., 2012). The majority of the affected individuals reside mainly in Africa, 
Mediterranean countries, Southeast Asian countries and Northern Europe (Sirdah et al., 
2012).  
Deficient in G6PD enzyme affects production of reactive nitrogen (RNS) and 
oxygen species (ROS), such as nitric oxide (NO), superoxide (O2•-), and hydrogen 
peroxide (H2O2), resulting in alterations of normal redox state of immune cells, which 
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produce cytokines and RNS/ROS in order to clear invading pathogens (Wu et al., 2008). 
Alteration of the redox state may render immune cells ineffective against invading 
organisms, resulting in an increased severity of the infection (Wu et al., 2008). Recent 
studies have indicated that the G6PD deficiency enhances viral replication and hence the 
virulence of a virus (Ho et al., 2008; Wu et al., 2008). Moreover, recurrence of 
microbial infections in G6PD-deficient individuals has been previously reported (Abu-
Osba et al., 1989; Costa et al., 2002). 
According to the findings of a study conducted in Thailand, G6PD-deficient 
individuals were significantly (19.1 %) prone to developing DHF/DSS compared to non-
G6PD-deficient individuals (Tanphaichitr et al., 2002). More recent study have shown 
that monocytes from G6PD-deficient individuals were more susceptible to DENV2 
infection with higher replication ability than those from healthy controls (Chao et al., 
2008). Although there appears to be a connection between G6PD-deficiency and 
increased severity of DENV2 infection, no studies have been carried out to elucidate the 
mechanism behind this relationship and the immune status. 
In Malaysia, so far no research has been conducted to investigate the association 
of G6PD deficiency as a genetic defect and dengue infection. Moreover, until now, there 
have been no studies on G6PD deficiency and its effect on cytokine production from 
DENV-infected monocytes of individuals with G6PD deficiency. 
1.2 Hypothesis 
Many genetic alterations have contributed to the development of dengue disease. 
One of the most recently identified genetic factors believed to be implicated in 
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pathogenesis dengue infection is G6PD-deficiency. It was hypothesized that monocytes 
from G6PD-deficient individuals will: 
• be more susceptible to DENV2 infection 
• produce lower levels of nitric and oxygen species following DENV2 infection.  
• accumulate higher oxidative stress following DENV2 infection 
• produce higher levels of cytokines following DENV2 infection 
1.3 General  of the Study 
To investigate the association between G6PD deficiency and DENV2 infection   
1.3 .1   Specific Objectives 
1. To find out whether monocytes from G6PD-deficient individuals were more 
susceptible to DENV2 infection 
2. To investigate the levels of nitrogen and oxygen species production following 
DENV2 infection in monocytes from G6PD-deficient individuals 
3. To investigate levels of oxidative stress accumulation following DENV2 
infection in monocytes from G6PD-deficient individuals 
4. To investigate the levels of cytokines production following DENV2 infection in 
monocytes from G6PD-deficient individuals 
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CHAPTER TWO 
LITERATURE REVIEW 
 
2.1 Dengue Virus (DENV) 
The DENV belongs to the genus flavivirus of the family Flaviviridae (Kurane, 
2007). There are four serotypes that are closely antigenically related and designated as 
DENV1, DENV2, DENV3 and DENV4 (Lindenbach & Rice, 2003). When humans are 
infected by one serotype, this stimulates long-life protection immunity against 
reinfection by the same serotype, but it does not protect the affected individual from 
infection with other serotypes (Gujarati & Ambika, 2012). 
2.1.1 Viral Composition 
DENV is a small spherical particle covered by a lipid-enveloped RNA virus. 
DENV is comprised of three structural proteins, which include capsid (Core C) protein, 
a membrane (M) protein, an envelope (E) protein and seven non-structural (NS1, NS2a, 
NS2b, NS3, NS4a, NS4b, and NS5) proteins as shown in Figure 2.1 (Lambeth, 2007). 
The E protein is the major surface protein that plays a key role in DENV entry and 
fusion into target cells (Rey, 2003). M protein is a small proteolytic fragment of prM 
protein, which is essential for growth and maturation of the virus into an infectious form 
that can attack new cells (Netsawang, 2010; Smit et al., 2011).  
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Figure 2.1: Dengue virus genome (Lambeth, 2007). The positive single stranded RNA is 
translated to capsid (C), pre-membrane (M), and envelope (E). The seven non-structural 
proteins as divided into NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5. 
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2.1.2 Dengue Virus Life Cycle and Replication  
DENV is a lipid-enveloped RNA flavivirus replicate in the cytoplasm of 
susceptible cells (Perera et al., 2008). Figure 2.2 summarized the initial stages of the 
viral life cycle start with bonding of the virus to the susceptible cells by receptor-
mediated endocytosis (Van Der Schaar et al., 2007; Perera et al., 2008). The entry 
process is initiated by the interaction of E protein with glycosaminoglycans and heparan 
sulphate on monocyte/macrophage target cells (Jain, 2005). After taking up the virus 
particles, the viruses are carried into endocytic compartment to form endosome in which 
low pH triggers a conformational change in the viral E and allows it to fuse with the 
endosomal membrane releasing the capsid into the cytoplasm. This mechanism has been 
reported with mosquito cells and human peripheral blood monocytes (Van Der Schaar et 
al., 2007; Perera et al., 2008; Umareddy, 2009).  
Once the viral RNA is in the cytoplasm, initiation of translation begins; the viral 
polyprotein is processed co- and post-transnationally into three functional viral proteins 
(C, prM, and E) and seven non-structural proteins (Perera et al., 2008). This processing 
is carried out by cellular and viral proteases. RNA replication is processed in the 
membrane-associated cytoplasmic compartment. Following virus proliferation, newly 
synthesized viral genome is encapsidated into the capsid proteins and directly buds into 
the endoplasmic reticulum where the immature virus (prM and E proteins) is surrounded 
by a lipid envelope containing viral proteins and budded off into the endoplasmic 
reticulum as undeveloped particles (Van Der Schaar et al., 2007; Netsawang, 2010). 
Some of these immature particles are transported to Golgi apparatus in which prM is 
cleaved to generate mature infectious particles in the low pH environment (Van Der 
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Schaar et al., 2007; Netsawang, 2010). Immature non-infectious and mature infectious 
particles are released into the extracellular space by exocytosis (Van Der Schaar et al., 
2007) 
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Figure 2.2: The flavivirus life cycle . A. Virions bind to cell-surface attachment 
molecules and receptors and are internalized through endocytosis. B. In the low pH of 
the endosome, viral glycoproteins mediate fusion of viral and cellular membranes, 
allowing disassembly of the virion and release of RNA into the cytoplasm. C. Viral 
RNA is translated into a polyprotein that is processed by viral and cellular 
proteases. D. Viral non-structural proteins replicate the genome RNA. E. Virus assembly 
occurs at the ER membrane, where capsid protein and viral RNA are enveloped by the 
ER membrane and glycoproteins to form immature virus particles. F. Immature virus 
particles are transported through the secretory pathway. In the low pH of the trans-Golgi, 
network (TGN) furin-mediated cleavage of prM drives maturation of the 
virus. G. Mature virus is released into the cytoplasm. Numbers shown in colored boxes 
refer to the pH of the respective compartments (Perera et al., 2008). 
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2.1.3 Epidemiology 
2.1.3.1 Global Epidemic of Dengue Infection 
In the 19th century, dengue infection was seen as a periodic disease, causing 
widespread infections at long intervals (Malavige et al., 2004; Netsawang, 2010). 
However, variation in this pattern has occurred and recently dengue surpassed other 
infections to rank the most serious mosquito-borne viral disease in the world. In the last 
50 years, its occurrence has increased 30-fold with considerable outbreaks in five of six 
World Health Organization (WHO) regions (Pinheiro & Corber, 1997; Malavige et al., 
2004).  
Globally, dengue infection is endemic in more than 120 countries worldwide and 
about 3 billion people are estimated to be at risk of acquiring dengue infection in tropical 
and subtropical regions as shown in figure 2.3 (Pinheiro & Corber, 1997; Malavige et 
al., 2004). Annually, approximately 100 million individuals suffer from self-limited an 
acute mild DF, while at least 500,000 incidences of DHF have been reported with 0.5% -
3.5% fatalities in Asian countries (Gubler & Clark, 1995; Malavige et al., 2004). 
Moreover, 90% of those suffering from DHF are children less than 15 years of age 
(Gubler & Clark, 1995; Malavige et al., 2004). 
In past centuries, in tropical regions of the world, outbreaks of DF occurred 
every 10 to 40 years (Luplertlop, 2005). This pattern has shifted dramatically in the last 
century and now DF and DHF occur every 3-5 years in many countries in Southeast 
Asia and are currently a major public health problem in seven of them (Malavige et al., 
2004). Epidemics of DF have been reported in the early 1900s, primarily in South Africa 
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(Gubler & Kuno, 1997), as well as in Yemen in the 1870s (Carey, 1971), and in 
Mediterranean. In the Southeast Asian countries, the number of outbreaks increased 
during and after the II World War (Gubler, 1998). However, since then, the situation had 
deteriorated, as there was a dramatic rise in frequency and in geographic extension of 
DF into Latin America and Brazil (Monath, 1994; Bozza et al., 2008). In the America, 
only few cases had been reported until the early 1980s, when a large outbreak in Cuba 
marked the start of epidemic spread to the Pacific and the American tropics (Monath, 
1994). 
The first outbreak of DHF in Asia was recorded in Manila, Philippines, in 1953-
1955 (Chaturvedi & Nagar, 2008), followed by an outbreak in Thailand in 1958. DHF 
epidemics in Singapore, Malaysia, and Vietnam were also reported in 1960s (Teo et al., 
2009). The incidence of DHF has increased dramatically in recent years with 
approximately five times more cases reported since 1980 than in the previous 30 years 
(Gubler & Meltzer, 1999). 
DENV infection now causes more illnesses and deaths than any other arboviral 
illness and has become a significant cause of morbidity and mortality in some parts of 
the world. Both DF and DHF affect people of all ages, with some studies showing 
highest incidence rates among infants and elderly (Rigau-Pérez et al., 1998; García-
Rivera & Rigau-Pérez, 2003). DHF mostly affects children under 15 years of age and 
women are more susceptible to the infection compared to men (Lye et al., 2010). The 
death rate decreases with increasing age, in particular above age of 50 (Guzmán et al., 
2002). The risk that a child will die during a secondary infection is nearly 15- fold 
higher compared to adults (Lye et al., 2010).  
15 
 
 
 
Figure 2.3: Countries and areas at risk of dengue transmission (Jelinek, 2009) 
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2.1.3.2 Dengue Infection in Malaysia 
In Malaysia, a century after its first reported occurrence in 1902 in Penang, 
dengue continues to be a serious health threat (Skae, 1902). It has become one of the 
major public health problems in both urban and suburban areas of Malaysia, especially 
after the emergence of DHF in 1962 (Rudnick et al., 1965). In 1982, the country 
underwent vast spread of the disease, with 3005 cases, of which 28.4% were cases of 
DHF with 35 deaths (Fang et al., 1984). Last available data suggested that the major DF 
and DHF outbreaks in Malaysia follow a periodic pattern, alternating every eight years 
(Bakar & Shafee, 2002). However, the frequency of these outbreaks had now changed to 
occur yearly and most cases are associated with severe complications (Senior, 2007). 
According to the data from Ministry of Health (MOH), all the states in 
Peninsular of Malaysia were evenly and similarly affected by the outbreaks. During the 
past 10 years, there has been a dramatic increase in DENV infections cases and the 
number of deaths (Figures 2.4 and 2.5.) Thus, the disease greatly affected the health, 
social and even economic life throughout the country. 
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Figure 2.4: Dengue cases within the last decade recorded among Malaysian population 
(MOH, 2010) 
 
 
Figure 2.5: Dengue death cases during the last decade among Malaysian population (MOH, 
2010) 
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2.1.4 Clinical Manifestations of Dengue Virus Infection 
2.1.4.1 Dengue Fever (DF) 
DF is an acute febrile illness characterized by the abrupt onset with a high fever 
between 39 and 40 oC that tends to last for 3-7 days. The fever is usually accompanied 
by severe malaise, headache, retro-orbital pain, myalgia, nausea, vomiting, epigastric 
pain, lymphadenopathy, weakness, and diarrhoea (Platt et al., 1997). In children, sore 
throat and abdominal pain are prevalent; thereafter, defervescence occurs between days 
3 and 8, and is usually followed by minor haemorrhagic phenomena (petechiae, purpura, 
epistaxis, gum bleeding, and menorrhagia) and the occurrence of a maculopapular 
(Gubler, 1998; Rigau-Pérez et al., 1998). 
In most cases, DF is self-limiting and the patient usually convalesces from the 
symptoms without complications 10 days after the onset of disease. Severe symptoms, 
such as haemorrhagic manifestations, are rare in DF patients, ranging from mild to 
severe in some cases, and are not restricted to only ‗dengue haemorrhage fever (Gubler, 
1998; Rigau-Pérez et al., 1998). Laboratory findings include leukopenia and 
thrombocytopenia and a positive result of the tourniquet test (Gubler, 1998; Rigau-Pérez 
et al., 1998). 
2.1.4.2 Dengue Haemorrhagic Fever (DHF)/ Dengue Shock Syndrome (DSS)  
DHF is a more severe form of dengue fever and mostly affects children under 15 
years, although it may also occur in adults (Lye et al., 2010). It is manifested as high 
fever, haemorrhage, increased vascular permeability, hepatomegaly and marked 
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thrombocytopenia (Gubler, 1998; Rigau-Pérez et al., 1998). Patients may also present 
with Vessele‘s leakage, which leads to plasma discharge, haemoconcentration, low pulse 
pressure, hypotension, heart failure, and shock, resulting in DSS (Gubler, 1998; Rigau-
Pérez et al., 1998). High serum levels of viral progeny, pro-inflammatory and ant-
inflammatory cytokines had been associated with DHF(Avirutnan et al., 2006).   
World Health Organization (WHO) grouped DHF into four grades. DHF grades 
1 and 2 are distinct from classical DF due to the affected individuals developing 
thrombocytopenia, hepatomegaly, and haemoconcentration(Gubler, 1998). DHF grades 
3 and 4 are classified as DSS, which is a more life-threatening dengue disease 
characterized by failure circulation due to a rapid and weak pulse, low pressure or 
hypotension with cold clammy skin and restlessness (Gubler, 1998).  
The dangerous phase of DSS is characterized by circulation failure that may 
occur at 24 hours before to 24 hours after the temperature falls to or below normal level 
(Dejnirattisai, 2004). The crisis usually lasts for 24 to 36 hours and the patients recover 
rapidly once convalescence starts (Dejnirattisai, 2004). The prognosis in DSS depends 
on prevention, early diagnosis and treatment of shock (Umareddy, 2009). Once a shock 
has set in, the fatality rate may be as high as 12 to 44% (Umareddy, 2009). The fatality 
among DSS patients is usually 25-50% or higher if not properly treated, and less than 
5% of such poor cases succumb to the disease, though recovery is rapid and without 
sequelae (Nimmannitya et al., 1987).  
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2.1.5 Dengue Pathogenesis  
DENV is introduced into a human host through the bite of an infected mosquito, 
whereby the virus establishes infection by replication in Langerhans cells and dentritic 
cells (DC) (Wu et al., 2000). It is subsequently disseminated and replicates via 
monocytes/macrophages (Wu et al., 2000). Pathogenesis of dengue disease depends 
upon a number of factors, such as viral virulence, antibody-dependent enhancement 
(ADE) (Halstead, 2007) and a number of host-specific factors that include age, 
race/ethnicity, genetic status, cytokines, and cellular immune response (Noisakran & 
Perng, 2008). The factors identified as responsible for the development of serious 
dengue diseases are viral virulence and abnormal host immune responses to infection 
(Sakuntabhai et al., 2005). 
2.1.5.1  Viral Virulence  
A number of researchers have studied the possible relationship between 
particular DENV serotypes and the severity of disease outcome, some reports indicating 
that DENV2 and DENV3 serotypes may cause more serious disease than the other 
serotypes, while DENV4 is responsible for a milder illness (Clyde et al., 2006; Mathew 
& Rothman, 2008). It is possible that certain genotypes within specific serotypes have 
also been associated with more severe disease of DHF. Generally, all Asian serotypes 
appear to be more virulent compared to those found in the Americas and the South 
Pacific (Clyde et al., 2006). According to phylogenetic analyses, DF is caused by the 
Native American DENV2 genotype, whereas the Asian DENV2 genotypes are 
associated with DHF (Cologna & Rico-Hesse, 2003).  
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Moreover, it was shown that the replication of Asian DENV2 genotype resulted 
in higher titers in human monocyte/macrophages and dentritic cells (DCs) compared to 
the American genotype (Rodenhuis-Zybert et al., 2010). Furthermore, when the ability 
of American and Asiatic lineage‘s genotypes to infect several population of Aide’s 
aegypti was analyzed, it was demonstrated that the overall infection rates were higher 
for the Asiatic DENV2 genotypes, so that the latter may be more transmittable 
(Armstrong & Rico-Hesse, 2003; Rodenhuis-Zybert et al., 2010). 
Maturation of DENV appears to be unproductive as dengue-infected mosquito 
and mammalian cells have been shown to secrete large numbers (up to 30%) of prM-
containing particles that play a role in dengue pathogenesis (Yu et al., 2008; Zybert et 
al., 2008; Rodenhuis-Zybert et al., 2010). Numerous studies have demonstrated that not 
fully mature particles lack the ability to infect cells and therefore, these particles are 
generally believed to be of minor importance in DENV pathogenesis (Rodenhuis-Zybert 
et al., 2010).  
2.1.5.2  Antibody-Dependent Enhancement (ADE) Infection 
Antibodies against dengue viruses play a significant role in the development of 
infection. Recently, several studies have shown a positive relationship between peak 
viremia titer and disease severity in humans, supporting the idea of the potential 
importance of ADE in enhancing dengue pathogenesis (Libraty et al., 2002).  
Following a primary DENV infection individuals typically develop cross-
reactive immune responses of two to three months in duration (Luplertlop, 2005). On the 
other hand, throughout a secondary infection with a different DENV serotype, a 
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preexisting, non-neutralizing, cross-reactive heterologous antibody recognizes the 
heterological infecting virus and forms an antigen-antibody complex (Luplertlop, 2005). 
The complex is bound to and internalized by immunoglobulin-FcR on the cell 
membrane of infected monocytes/macrophages (Luplertlop, 2005; Wahala & de Silva, 
2011). As the antibody is heterologous, the heterologous virus is not neutralized and is 
free to replicate inside a monocytes. This mechanism, known as ADE, enhances the 
infection and replication of dengue virus in monocytes, resulting in the increasing 
number of dengue-infected cells and levels of viremia, leading to DHF/DSS (Luplertlop, 
2005; Martina et al., 2009; Wahala & de Silva, 2011).  
The occurrence of DHF during primary dengue virus infection in the first year of 
life in children who have acquired antibody against dengue viruses transplacentally from 
dengue-immune mothers also supports the idea of an in vivo role for ADE (De Rivera et 
al., 2008).  
2.1.5.3  Cellular Immune Response in Dengue Virus Infection 
At present, the focus of the researchers has shifted towards studying aspects of 
cell-mediated immune responses in the pathogenesis of DHF (Malavige et al., 2004). 
The DENV can infect CD4+ and CD8+ T-cell lines in vitro (Malavige et al., 2004; 
Nielsen, 2009), even though there is no evidence of CD4+ and CD8+ T-cells serving as 
a target for dengue virus in vivo (Theofilopoulos et al., 1976). There is strong evidence 
that a high level of T-cell activation is associated with DHF (Green et al., 1999a). 
Moreover, primary infection induces activation of both serotype-specific and serotype-
cross-reactive T-cells against DENV infection. On secondary infection, CD4+ and 
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CD8+ T-cells were shown to enhance severity of infection by producing various 
cytokines (Kurane & Ennis, 1994). Thus, enhanced cytokine production indicates severe 
pathogenesis of DHF/DSS (Chaturvedi et al., 2005). 
2.1.5.4   Cytokine Response in Dengue Infection  
The immune system maintains the physiological integrity of the body mainly by 
eradicating foreign material and infectious pathogens (Chaturvedi et al., 2004). During 
the process of virus establishing an infection, the host responds by initiating a complex 
defence system by means of phagocytic cells, in order to eradicate and clear the virus 
from the host (Matsukawa et al., 2000).  
The most severe forms of dengue disease are associated with high viral titers and 
cytokines. Both host genetic determinants and virus characteristics contribute to viral 
replication; however, rapid replication during the short viraemic period of acute 
infection can be achieved only if innate immunity, which represents the first line of host 
defence against pathogens, is delayed or inhibited (Mazzon, 2010). The more efficient 
the evasion of innate immunity, the higher will be the viral titer and cytokine production, 
and the more severe the disease outcome (Mazzon, 2010).  
Phagocyte cells that serve as the first line of defence in innate immunity play 
important role in neutralizing and eliminating pathogens (Matsukawa et al., 2000). In 
contrast, the adaptive immune response is responsible for permanent protection, taking 
days to develop antigen-specific T-cell receptor (cell-mediated immunity) and 
immunoglobulin (Esche et al., 2005).  
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During an infection, both innate and adaptive immune responses play a key role 
in cytokine and chemokine release (Esche et al., 2005). Inflammatory and anti-
inflammatory cytokines might be released either directly from infected monocytes or 
after interactions with immune cells (Esche et al., 2005; Luplertlop, 2005). 
Consequently, a number of cytokines are produced, and the complex network of 
induction further increases the cytokine levels, resulting in the increased vascular 
permeability, plasma leakage, shock, and the coagulation system dysfunction, which 
may lead to DHF/DSS (Luplertlop, 2005; Nielsen, 2009). 
2.1.5.4.1  Role of Cytokines in Pathogenesis of DF and DHF 
Cytokines are groups of soluble proteins with low molecular weight that are 
produced by different immune cells—autocrine and paracrine regulators—that affect and 
regulate the activity of target cells (Berczi & Szentivanyi, 2003). In DENV infection, 
cytokines play an important role in the disease severity, homeostasis regulation (Bozza 
et al., 2008) and immunopathogenesis of the DENV infection (Chen & Wang, 2002).  
In fact, all immune-system cells seem to be activated during dengue infection 
and produce cytokines, such as T-cells producing helper Th1 and Th2 cytokines during 
DENV infection (Rabablert, 2005). Th1 cells produce IFN-, IL-2 and TNF-α, which are 
responsible for cell-mediated inflammatory reactions and tissue injury infection 
(Rabablert, 2005). Th2 cells produce IL-4, IL-5, IL-6, IL-10 and IL-13, which help B-
cells to secrete antibodies (Chaturvedi et al., 2000; Rabablert, 2005). The cytokine 
profiles produced in patients with DF include IFN- and IL-2, as well as slightly 
increased levels of IL-4, IL-6 and IL-10, which is a typical Th1-type response 
